Altimmune announces Q3 earnings per share of 21 cents, below consensus estimate of 27 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy ALT?
Q3 Revenue Report: Altimmune reported Q3 revenue of $5,000, significantly below the consensus estimate of $560,000, while highlighting advancements in their pemvidutide MASH program.
Upcoming Milestones: The company anticipates two key milestones, including an End-of-Phase 2 meeting with the FDA and the release of 48-week data from the IMPACT trial, which will inform the design of their Phase 3 MASH trial.
RECLAIM Trial Progress: Altimmune has completed patient recruitment for the RECLAIM trial focused on pemvidutide for alcohol use disorder, indicating a strong unmet need in this area.
Leadership Additions: The company is enhancing its management team with new appointments, including Dr. Christophe Arbet-Engels as Chief Medical Officer, Linda Richardson as Chief Commercial Officer, and Robin Abrams as Chief Legal Officer, all of whom bring significant expertise.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.460
Low
12.00
Averages
16.00
High
20.00
Current: 4.460
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune to Report Q4 2025 Financial Results on March 5
- Earnings Report Schedule: Altimmune is set to release its Q4 2025 financial results on March 5, 2026, providing crucial insights into the company's financial health and future growth trajectory, which is vital for investor confidence.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and answer investor questions, with the call being webcast live on the company's Investor Relations website to ensure transparency and timely information dissemination.
- Replay Availability: A replay of the conference call will be accessible on the Investor Relations website shortly after the call, available for up to three months, allowing investors who cannot attend live to catch up on key insights and discussions.
- Company Background: Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, with its lead candidate pemvidutide targeting metabolic dysfunction-associated steatohepatitis and showing promising market potential, which could significantly impact its growth prospects.
See More
Analysis of Weight Loss Drug Market Prospects
- Challenges for Altimmune: Altimmune's leading candidate pemvidutide showed reasonable efficacy in a 2023 phase 2 trial, but high patient discontinuation rates due to adverse reactions highlight the risks and uncertainties it faces in the weight loss drug market.
- FDA Breakthrough Therapy Designation: Despite mixed phase 2 data in MASH, pemvidutide received Breakthrough Therapy designation from the FDA, indicating its potential in high unmet need areas; if it successfully passes phase 3 trials, it could significantly enhance Altimmune's market value.
- Novo Nordisk's Market Position: Facing competition from Eli Lilly, Novo Nordisk has lowered its sales guidance, yet with the approval of Wegovy and the launch of a new oral GLP-1 drug, it is poised for recovery in the coming years, demonstrating a stronger market outlook.
- Investor Outlook: 2026 is seen as a transition year for Novo Nordisk; although sales may decline this year, the anticipated impact of new approvals and label expansions is expected to gradually boost revenue, showcasing its long-term investment value in the weight loss drug market.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Altimmune to Report Q4 2025 Financial Results on March 5
- Earnings Report Schedule: Altimmune is set to release its Q4 2025 financial results on March 5, 2026, providing crucial insights into the company's financial health and future growth trajectory, which is vital for investor confidence.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and answer investor questions, with the call being webcast live on the company's Investor Relations website to ensure transparency and timely information dissemination.
- Replay Availability: A replay of the conference call will be accessible on the Investor Relations website shortly after the call, available for up to three months, allowing investors who cannot attend live to catch up on key insights and discussions.
- Company Background: Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, with its lead candidate pemvidutide targeting metabolic dysfunction-associated steatohepatitis and showing promising market potential, which could significantly impact its growth prospects.
See More
Analysis of Weight Loss Drug Market Prospects
- Challenges for Altimmune: Altimmune's leading candidate pemvidutide showed reasonable efficacy in a 2023 phase 2 trial, but high patient discontinuation rates due to adverse reactions highlight the risks and uncertainties it faces in the weight loss drug market.
- FDA Breakthrough Therapy Designation: Despite mixed phase 2 data in MASH, pemvidutide received Breakthrough Therapy designation from the FDA, indicating its potential in high unmet need areas; if it successfully passes phase 3 trials, it could significantly enhance Altimmune's market value.
- Novo Nordisk's Market Position: Facing competition from Eli Lilly, Novo Nordisk has lowered its sales guidance, yet with the approval of Wegovy and the launch of a new oral GLP-1 drug, it is poised for recovery in the coming years, demonstrating a stronger market outlook.
- Investor Outlook: 2026 is seen as a transition year for Novo Nordisk; although sales may decline this year, the anticipated impact of new approvals and label expansions is expected to gradually boost revenue, showcasing its long-term investment value in the weight loss drug market.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
